Supplementary Information

Contact inhibition controls cell survival and proliferation via YAP/TAZ-autophagy axis

Pavel et al.
Supplementary Fig. 1: High confluency cells have fewer autophagosomes and accumulate aggregate-prone proteins/autophagy substrates when compared to low confluency cells.

(a) Endogenous LC3 immunostaining in MCF10A cells plated on the same coverslip. Areas with sparse and dense cells were imaged by confocal microscopy. Quantification of LC3 dots per cell (more than 30 cells were counter per condition) is shown in the right panel (**P<0.01; two-tailed t-test).

(b) Representative LC3-II immunoblotting at low and high confluencies in HeLa cells. HeLa cells plated at various densities were cultured for 48 hours and exposed to either DMSO or BafA1 (400 nm) for the last 6 hours.

(c) Representative LC3-II immunoblotting at low and high confluencies in HaCaT cells. HaCaT cells plated at various densities were cultured for 48 hours and exposed to either DMSO or BafA1 (400 nm) for the last 6 hours.

(d) Representative LC3-II immunoblotting at low and high confluencies in primary MEFs. Primary MEFs plated at various densities were cultured for 48 hours and exposed to either DMSO or BafA1 (400 nm) for the last 6 hours.

(e) DAPI staining for the experiment described in (d).

(f) Average cell area of MCF10A cells plated at LC, HC and 2HC. At least 20-30 cells were quantified per condition. Bars represent the mean±s.e.m. (***P<0.001; two-tailed t-test).
(g) Representative confocal images of primary mammary epithelial cells (pMECs) from transgenic mice expressing mRFP-GFP-LC3 plated at different confluencies: LC and HC. Scale bar is 10 µm.

(h) Quantification of total number of GFP (autophagosomes) and mRFP dots (autophagosomes and autolysosomes) in pMECs treated as in (h). At least 20-30 cells were quantified per condition. Bars represent the mean±s.e.m. (***P<0.001; two-tailed t-test).

(i) Number of GFP (autophagosomes) and mRFP dots (autophagosomes and autolysosomes) in HeLa cells. HeLa cells stably expressing mRFP-GFP-LC3 were seeded at LC and HC and subjected to automated Cellomics visualization and analysis. Bars represent the mean±s.d. (n=3; **P<0.01; two-tailed one sample t-test). More than 600 cells were counted per condition, per experiment.

Note: Throughout the figures, n = number of independent biological replicates unless otherwise stated.
Supplementary Figure 2: High confluency cells have increased levels of aggregate-prone proteins/autophagy substrates when compared to low confluency cells, despite mTORC1 inhibition.

(a) Representative western-blots of p62 in MCF10A cells. GAPDH was used as loading control. Quantification of p62 densitometry relative to GAPDH is shown on the right. Bars represent the mean±s.d. (n=3; *P<0.05; two-tailed one sample t-test).

(b) Representative confocal images of HeLa cells transfected with N17-97QP-GFP and then reseeded at low (LC) and high (HC) confluencies. Bars represent the relative ratio of percentages of cells with aggregates between HC and LC conditions (n=3; *P<0.05; two-tailed t-test). Scale bar is 10 µm.

(c) Representative western-blots of A53T-synuclein tagged with GFP in MCF10A cells. GAPDH was used as loading control. Quantification of A53T-synGFP densitometry relative to empty GFP is shown on the bottom panel:
mean±s.d. (one representative experiment in triplicates: ***$P<0.001$; two-tailed t-test). The experiment was repeated with similar results.

(d) Representative western-blot of A53T-synuclein tagged with GFP in HeLa cells. Quantification of A53T-synGFP densitometry relative to empty GFP is shown on the bottom panel: mean±s.d. (one representative experiment in triplicates: **$P<0.01$; two-tailed t-test). The experiment was repeated with similar results.

(e) Representative western-blot of the indicated mTORC1 (P70-S6K) and mTORC2 (AKT) substrates in MCF10A cells. GAPDH was used as loading control.

(f) Representative western-blot of the mTORC2 substrate, pAkt(S473) in primary MEFs. Gapdh was used as loading control.

(g) Representative western-blot of pULK1(S555) (a well-characterised AMPK substrate) in MCF10A cells. Quantification of pULK1(S555) densitometry relative total ULK1 levels is shown on the bottom panel: mean±s.d. (one representative experiment in triplicates: **$P<0.01$; two-tailed t-test). The experiment was repeated with similar results.
Supplementary Fig. 3: YAP/TAZ localization and proliferation at different cell confluencies.

(a) Representative images of YAP/TAZ and BrdU immunostainings in MCF10A cells seeded at increasing confluencies. Percentages of cells with either nuclear (Nc) or cytoplasmic (Cyt) localization for YAP/TAZ are shown on the top graph. Percentages of cells with positive BrdU immunostaining are shown on the bottom panel. Scale bar throughout the panel is 10 µm.

(b) Representative images of YAP/TAZ and BrdU immunostainings in primary MEFs seeded at low and high confluencies. The graphs show the percentages of cells with nuclear or cytoplasmic localization and the percentages of BrdU-positive cells. Nc = nucleus, Cyt = cytosol. Scale bar is 10 µm.
(c) Representative images of YAP/TAZ and immunostaining in HeLa cells seeded at low and high confluencies. The graphs show the percentages of cells with nuclear or cytoplasmic localization (more than 400 cells were counted per condition) and the percentages of BrdU-positive cells (more than 600 cells were counted per condition). Nc = nucleus, Cyt = cytosol.

(d) Representative images of YAP/TAZ immunostaining in HaCaT cells seeded at low and high confluencies.

(e) Luciferase assay for YAP/TAZ activity in MCF10A cells plated at low (LC) or high (HC) confluency as described in Methods.
Supplementary Fig. 4: YAP and TAZ double knockdown compromises autophagy.

(a) LC3-II levels assessed by immunoblotting in MCF10A cells exposed to either control (Ctrl) or YAP siRNAs. The cells were treated with vehicle (DMSO) or bafilomycin A1 (BafA1). GAPDH was used as loading control. The graphs show the LC3-II/GAPDH densitometry: mean±s.e.m. (n=5; NS - not significant; two-tailed one sample t-test).

(b) LC3-II levels assessed by immunoblotting in MCF10A cells exposed to control (Ctrl), YAP/TAZ (both genes knocked down) or TAZ siRNAs. The cells were treated with vehicle (DMSO) or bafilomycin A1 (BafA1). GAPDH was used as loading control. The graphs show the LC3-II/GAPDH densitometry: mean±s.d. of one representative experiment (n=3; ***P<0.001, *P<0.05, NS - not significant; two-tailed one sample t-test).

(c) LC3-II levels assessed by immunoblotting in MCF10A cells exposed to either control (Ctrl) or YAP/TAZ siRNAs (YAP and TAZ double knockdown). The cells were treated with vehicle (DMSO) or bafilomycin A1 (BafA1) at 200 nM for 12 hours. GAPDH was used as loading control. The graphs show the LC3-II/GAPDH densitometry: mean±s.d. (n=3 independent experiments performed in triplicates; *P<0.05; two-tailed one sample t-test).

(d) LC3-II levels assessed by immunoblotting in HeLa cells exposed to either control (Ctrl) or YAP/TAZ siRNAs. The cells were treated with vehicle (DMSO) or bafilomycin A1 (BafA1) at 200 nM for 12 hours. GAPDH was used as loading control. The graphs show the LC3-II/GAPDH densitometry: mean±s.e.m. (n=4; ***P<0.001, *P<0.05; two-tailed one sample t-test).

(e) Representative images of GFP-LC3 dots in HeLa cells stably expressing GFP-LC3. HeLa cells were exposed to either Ctrl or YAP/TAZ siRNAs. Quantification of GFP-LC3 dots numbers is shown on the right panel (n=6 wells of at least 100 cells counted per well; *P<0.05; two-tailed t-test). Scale bar throughout the panel is 10 µm.

(f) Representative LC3-II immunobLOTS (longer and shorter exposures) assessed in HeLa cells exposed to either control (Ctrl) or individual YAP + TAZ siRNA oligos for 96 hours (pair 1 (YAP/TAZ_p1) and pair 2 (YAP/TAZ_p2), respectively). The cells were treated with vehicle (DMSO) or bafilomycin A1 (BafA1). GAPDH was used as loading control. The graphs show the LC3-II/GAPDH densitometry: mean±s.e.m. (n=3; ***P<0.001, **P<0.01; two-tailed one sample t-test).

(g) Representative LC3-II immunoblot assessed in HeLa cells exposed to either control (Ctrl) or individual YAP and TAZ siRNA oligos for 36 hours (pair 1 (YAP/TAZ_p1) and pair 2 (YAP/TAZ_p2), respectively). GAPDH was used as loading control. Bars represent the mean±s.d. (one representative experiment in triplicates: ***P<0.001, **P<0.01; two-tailed t-test).

(h) Representative LC3-II immunoblot in HeLa cells exposed to increasing concentrations of verteporfin for 16 hours. LC3-II levels were quantified in the absence or presence of bafilomycin A1 (400 nM) for the last 4 hours. The experiment was performed in triplicates and repeated at least twice with similar results: mean±s.d. (**P<0.001, **P<0.01; two-tailed one sample t-test).

(i) Luciferase assay for YAP/TAZ activity in HeLa cells exposed to increasing concentrations of verteporfin for 4 hours. Bars represent the mean±s.d. (**P<0.01, *P<0.05; one-way ANOVA).

(j) Luciferase assay for YAP/TAZ activity in HeLa cells exposed to increasing concentrations of verteporfin for 8 hours. Bars represent the mean±s.d. (**P<0.001, *P<0.05; one-way ANOVA).

(k) Representative LC3-II immunoblot assessed in high confluency cells exposed to increasing concentration of verteporfin (0, 2.5, 5 µM) in the presence of BafA1.

(l) Representative LC3-II immunoblot assessed in MCF10A cells transfected with either miR control or miR-375. Bars represent the mean±s.e.m. (n=4; **P<0.01; two-tailed one-sample t-test).
Supplementary Fig. 5: LATS1/2 knockdown rescues the autophagy defects seen in high confluency cells via YAP/TAZ activation.
(e) Representative LC3-II immunoblot in HeLa cells overexpressing either YAP(5SA) or YAP(5SA/S94A) in the presence of BafA1. Cells were either or not exposed to Torin1 (used as mTORC1 inhibitor). See Fig. 1h for LC3-II quantification.

(b) Representative western-blot of the indicated mTORC1 and mTORC2 substrates in HeLa cells overexpressing either YAP(5SA) or YAP(5SA/S94A).

(c) Representative images of YAP/TAZ immunostaining in highly confluent MCF10A cells exposed to LATS1/2 double knockdown. Scale bar is 10 µm.

(d) Representative images of endogenous immunostaining of LC3 in MCF10A cells treated as in (e). Quantification of number of LC3 dots per cell is shown in the bottom panel, presented either as the mean±s.d. (***P<0.001; two-tailed one sample t-test) or as percentages of cells with more than 20 dots per cell. More than 35 cells were counted per LC condition and more than 70 cells were counted per HC condition. The experiment was repeated with similar results at least another two times. YAP/TAZ cytoplasmic localization at high cell density is rescued by LATS1/2 KD (Nc = nucleus; Cyt = cytosol). See Fig. 1k.

(e) Representative immunoblots of the indicated proteins and LC3-II/GAPDH densitometry in MCF10A cells exposed to either control or individual pairs of LATS1 + LATS2 (LATS1/2_p1) and YAP + TAZ (Y/T_p1) siRNA oligos. The cells were treated with vehicle (DMSO) or bafilomycin A1 (BafA1). Bars represent the mean±s.d. (n=3: ***P<0.001, *P<0.05; two-tailed one sample t-test). Distinct oligos were used in parallel experiment in (f).

(f) Representative immunoblots of the indicated proteins and LC3-II/GAPDH densitometry in MCF10A cells exposed to either control or individual pairs of LATS1 + LATS2 (LATS1/2_p2) and YAP + TAZ (Y/T_p2) siRNA oligos. The cells were treated with vehicle (DMSO) or bafilomycin A1 (BafA1). Bars represent the mean±s.d. (n=3: **P<0.01, *P<0.05; two-tailed one sample t-test). Distinct oligos were used in parallel experiment in (e).

(g) LC3-II in cells overexpressing MST2-GFP.

For all immunoblots, GAPDH was used as loading control.
Supplementary Fig. 6: Expression of actin related proteins is reduced in high confluency cells.

(a) Gene ontology analysis of genes previously identified as potential targets of YAP through ChIP-Seq. See Methods.

(b) Actin cytoskeleton gene ontology analysis for the selected potential targets (see (a)). Myosin complex and myosin-II form distinct groups.

(c) mRNA levels of CYR61 and CTGF relative to GAPDH in MCF10A cells plated at LC and HC. See also Fig. 2a. Bars – mean±s.e.m. (n=4; ***P<0.001; two-tailed one sample t-test).

(d) mRNA levels of the indicated proteins relative to Rplp0 in primary MEFs at LC and HC. Bars – mean±s.e.m. (n=4; ***P<0.001, **P<0.01, *P<0.05; two-tailed one sample t-test).

(e-f) mRNA levels of the indicated proteins relative to GAPDH in HeLa cells (e) plated at LC and HC or (f) exposed to either control (Ctrl) or smart-pool YAP/TAZ siRNAs. Bars – mean±s.d. (n=3; ***P<0.001, **P<0.01, *P<0.05, NS – not significant; two-tailed t-test).

(g) mRNA levels of RPLP0 relative to GAPDH in MCF10A cells plated as in (c). Bars – mean±s.e.m. (n=4; ***P<0.001; two-tailed one sample t-test).

(h) mRNA levels of the indicated proteins relative to GAPDH in HeLa cells exposed to YAP/TAZ siRNAs using the autophagy qPCR array (Qiagen).

(i) Representative western-blots for of the indicated proteins in MCF10A cells plated at different confluencies: LC or HC (left panel) and treated with YAP/TAZ siRNAs (right panel).

(j) Representative western-blots for the indicated proteins in MCF10A cells plated at various densities and exposed to YAP/TAZ siRNAs.

(k) Representative MLC2 immunoblot in HeLa cells exposed to increasing concentrations of verteporfin for 16 hours. MLC2 levels were quantified in the absence or presence of bafilomycin A1 (400 nM, 4 hours) relative to GAPDH, used as a loading control. MLC2 was revealed by ECL, while GAPDH was stained with LICOR secondary antibodies.

(l) Putative TEAD-binding sites in the promoter regions of the selected genes. The grey square corresponds to the ‘CATTCC’ motif, while the blue rectangular corresponds to the ‘GGAATG’ motif. The red line underlies the motifs included in the ChIP regions.

(m) Negative controls for Fig. 2e.

(n) Positive and negative controls for Fig. 2e. Bars – mean±s.d. (one representative experiment in triplicates; ***P<0.001, **P<0.01; two-tailed t-test).
Supplementary Fig. 7: YAP/TAZ knockdown reduces the amount of actin stress fibers.

(a) Representative confocal images of HeLa cells exposed to either control or two individual pairs of YAP + TAZ siRNA oligos (using two distinct pairs: either YAP/TAZ_p1 or YAP/TAZ_p2). HeLa cells were immunostained for endogenous YAP/TAZ and F-actin cytoskeleton (Phalloidin 488). Scale bars are 10 µm.

(b) Representative confocal images of MCF10A cells exposed to either control or individual pairs of LATS1 + LATS2 (LATS1/2_p1) and YAP + TAZ (Y/T_p1) siRNA oligos. MCF10A cells were immunostained for endogenous YAP/TAZ and F-actin. Scale bars are 10 µm. Distinct oligos were used in parallel experiment in (c).

(c) Representative confocal images of MCF10A cells exposed to either control or individual pairs of LATS1 + LATS2 (LATS1/2_p2) and YAP + TAZ (Y/T_p2) siRNA oligos. MCF10A cells were immunostained for endogenous YAP/TAZ and F-actin. Scale bars are 10 µm. Distinct oligos were used in parallel experiment in (b).
Supplementary Fig. 8: Double LATS1/2 and NF2 knockdown rescues YAP/TAZ localisation and F-actin stress fibers in MCF10A cells plated at HC.

(a) Representative confocal images of MCF10A cells exposed to either control or (LAST1/2 + NF2) siRNA oligos. MCF10A cells plated at various confluencies were immunostained for endogenous YAP/TAZ and F-actin. Scale bars are 10 µm.

(b) Percentage of MCF10A cells with either nuclear (Nc) or cytoplasmic (Cyt) YAP/TAZ localization. The cells were treated as in (a).
Supplementary Fig. 9: YAP(5SA) rescues the formation of actin stress fibers in high confluency HeLa cells

Representative confocal z-stacks of HeLa cells overexpressing control (empty flag), YAP(5SA) or YAP(5SA/S94A) were immunostained for endogenous YAP/TAZ and F-actin. Scale bars are 10 µm.
Supplementary Fig. 10: The decrease in ATG9A – LC3 colocalisation is YAP/TAZ-dependent in high confluency cells.

Representative images of LC3 and ATG9A double immunostaining in MCF10A cells plated at LC or HC confluencies and exposed to either LATS1/2_p1 alone or combined with YAP/TAZ_p1 siRNAs. Scale bar is 10 µm. See Fig. 3e.
Supplementary Fig. 11: The decrease in ATG9A – LC3 colocalisation is YAP/TAZ-dependent in high confluency cells.

Representative images of LC3 and ATG9A double immunostaining in MCF10A cells plated at LC or HC confluencies and exposed to either LATS1/2_p2 alone or combined with YAP/TAZ_p2 siRNAs. Scale bar is 10 µm.
**Figure S19**

**a**

LC

| Condition          | LC3 | ATG9A | DAPI | LC3 | ATG9A | merged |
|--------------------|-----|-------|------|-----|-------|--------|
| Ctrl               |     |       |      |     |       |        |
| LATS1/2 KD         |     |       |      |     |       |        |
| LATS1/2 KD + Blebbistatin |     |       |      |     |       |        |

HC

| Condition          | LC3 | ATG9A | DAPI | LC3 | ATG9A | merged |
|--------------------|-----|-------|------|-----|-------|--------|
| Ctrl               |     |       |      |     |       |        |
| LATS1/2 KD         |     |       |      |     |       |        |
| LATS1/2 KD + Blebbistatin |     |       |      |     |       |        |

**b**

![Bar chart showing ATG9A-LC3 colocalisation](chart)

- **Legend**
  - Ctrl
  - LATS1/2 KD
  - LATS1/2 KD + Blebbistatin

**Significance**

- **PC**
  - LC: ***
  - HC: ***

- **M1**
  - LC: ***
  - HC: ***
Supplementary Fig. 12: The decrease in ATG9A – LC3 colocalisation is myosin-dependent in high confluency cells.

(a) Representative images of LC3 and ATG9A double immunostaining in MCF10A cells plates at LC and HC confluencies. MCF10A cells were transfected with either control or LATS1/2 siRNAs, plated at low and high confluencies and exposed to either DMSO (vehicle control) or blebbistatin (20 µM). Scale bar is 10 µm.

(b) ATG9A – LC3 colocalization in MCF10A cells plated and treated as in (a). The Pearson’s correlation and Manders’ overlap (the amount of LC3 in the ATG9 compartment) coefficients were used to measure the colocalization of LC3 with ATG9A. Bars – mean±s.e.m. (for LC: n=25 cells, for HC: n=100 cells; ***P<0.001; two-tailed t-test).
Supplementary Fig. 13: Cell suspension increases LC3-II levels only in MCF10A cells initially plated at LC (not HC).

(a) LC3-II levels assessed by immunoblotting in MCF10A cells plated at LC and then trypsinized and kept in suspension for various time points (6 and 12 hours). The graphs show the mean±s.d. (one representative experiment in triplicates; ***P<0.001, **P<0.01; two-way ANOVA). The experiment was repeated with similar results.

(b) LC3-II levels assessed by immunoblotting in HeLa cells plated at LC and then trypsinized and kept in suspension for various time points (6 and 12 hours). The graphs show the mean±s.d. (one representative experiment in triplicates; **P<0.01, *P<0.05; two-way ANOVA). The experiment was repeated with similar results.

(c) LC3-II levels assessed by immunoblotting in MCF10A cells plated at HC and then trypsinized and kept in suspension for various time points (6 and 12 hours). The graphs show the mean±s.d. (one representative experiment in triplicates; *P<0.05, NS – not significant; two-way ANOVA). The experiment was repeated with similar results.

(d) LC3-II levels assessed by immunoblotting in HeLa cells plated at LC and then scraped and kept in suspension for various time points (6 and 12 hours). The graphs show the mean±s.d. (one representative experiment in triplicates; *P<0.05, NS – not significant; two-way ANOVA). The experiment was repeated with similar results.

(a-d) The cells were treated with vehicle (DMSO) or bafilomycin A1 (BafA1) at 400 nM for the last 4 hours. GAPDH was used as loading control.
Supplementary Fig. 14: MCF10A cells plated at LC attach faster than those plated at HC.

(a) Representative DAPI/ Bright field images for MCF10A cell attachment. MCF10A cells were initially plated at LC and HC, then trypsinized and equal number of cells were seeded on coverslips and left to attach for 4, 8, 12 and 24 hours.

(b) Number of attached MCF10A cells per bright field at each indicated time point. The cells were treated as in (a). The graphs show the mean±s.e.m. (n=4; ***P<0.001, *P<0.05; two-way ANOVA).
Supplementary Fig. 15: Cell viability is both YAP- and autophagy-dependent in high confluency HeLa cells under hypoxia and no glucose conditions.

(a) Propidium iodide (PI) staining and cell viability data measured by flow cytometry using the annexin5-FITC/PI method. HeLa cells exposed to control, ATG7/ATG10 or ATG16L1 siRNAs were transfected with control (empty flag vector), YAP(5SA) or YAP(5SA/S94A) and grown, for the last 16 hours, in hypoxia and no glucose conditions.
(b) Bars represent the mean of 2 independent experiments (Exp #1 – green dot-plot and Exp #2 – black dot-plot).
(c) The efficiency of autophagy gene knockdowns in HeLa cells.
| Condition                        | Ctrl | YAP(5SA) | YAP(5SA/S94A) |
|---------------------------------|------|----------|---------------|
| Ctrl (Normoxia 21% O₂)          |      |          |               |
| YAP(16S)                        |      |          |               |
| Ctrl (Normoxia 1% O₂, no glucose) |      |          |               |
| YAP(5SA)                        |      |          |               |
| ATG7/16 KD (Hypoxia 1% O₂, no glucose) |      |          |               |
| YAP(5SA)                        |      |          |               |
| ATG16L1 KD (Hypoxia 1% O₂, no glucose) |      |          |               |
| YAP(5SA)                        |      |          |               |

**Graph b**

- **b** Percentage of MCF10A cells positive for PI (%)
- **c** ATG7/10 KD
- **c** ATG16L1 KD

**Legend**
- Ctrl
- YAP(5SA)
- YAP(5SA/S94A)

**Conditions**
- Normoxia 21% O₂
- Hypoxia 1% O₂, no glucose
Supplementary Fig. 16: Cell viability is both YAP- and autophagy-dependent in high confluence MCF10A cells under hypoxia and no glucose conditions.

(a) Propidium iodide (PI) staining in MCF10A cells exposed to control, ATG7/ATG10 or ATG16L1 siRNAs and transfected with control (empty flag vector), YAP(5SA) or YAP(5SA/S94A). The cells were grown in hypoxia and no glucose conditions for the last 16 hours.

(b) Quantification of PI-positive cells by flow cytometry in MCF10A cells treated as in (a). Bars represent the mean±s.e.m. (n=6; ***P<0.001, **P<0.01, *P<0.05, NS – not significant; two tailed t-test).

(c) The efficiency of the indicated autophagy gene knockdowns in MCF10A cells.
Supplementary Fig. 17: The apoptosis in high confluency cells is both YAP- and autophagy-dependent under hypoxia and glucose starvation conditions.

(a) MCF10A cells overexpressing control (empty flag vector), YAP(5SA) or YAP(5SA/S94A) were treated with either control (DMSO) or VPS34-IN1 and exposed to combined hypoxia and glucose-starvation conditions. These cells were stained with Propidium Iodide (PI) and the cell viability data was measured by flow cytometry. Bars represent the mean±s.e.m. (*P<0.05, **P<0.01, ***P<0.001, NS – not significant; two tailed t-test).

(b) YAP/TAZ localization in MCF10A cells plated at low confluency and grown under either normoxia or hypoxia + glucose starvation conditions. Percentages of cells with either nuclear or cytoplasmic localization are shown in the right panel: more than 400 cells were counted per condition.

(c) HIF1α immunoblot for the cells treated as in (b).

(d) Luciferase assay for YAP/TAZ activity in MCF10A cells transfected with either control or LATS1/2 siRNAs, plated at low confluency and grown under either normoxia or hypoxia + glucose starvation conditions.
(e) Representative images of YAP/TAZ and F-actin (Phalloidin 488) in HeLa cells plated at low confluency and grown under either normoxia or hypoxia and glucose starvation conditions. Percentages of cells with either nuclear or cytoplasmic localization are shown in the right panel: more than 400 cells were counted per condition. Scale bars throughout the panel are 10 µm.

(f) Quantification of YAP/TAZ localization for the HeLa cells treated as in (e).
Supplementary Fig. 18: The apoptosis in soft matrix is both YAP- and autophagy-dependent under hypoxia and glucose starvation conditions.

(a) Representative p62 immunoblot in MCF10A cells seeded on ECM with different stiffnesses.

(b) Apparent stiffness $K_{app}$ of various collagen-based matrixes determined by AFM indentation experiments. See Methods.
(c) Quantification of YOYO-1 negative and positive MCF10A cells plated on stiff or soft ECM and exposed or not to hypoxia and glucose starvation (more than 200 cells were counted per each condition). The experiment was repeated with similar results.

(d) Quantification of YOYO-1 negative and positive MCF10A cells plated on stiff or soft ECM and exposed or not to hypoxia and glucose starvation (more than 200 cells were counted per each condition). The cells were initially exposed to control, LATS1/2, ATG7/ATG10 or ATG16L1 siRNAs. The experiment was repeated with similar results.

(e) Representative images of YOYO-1 staining in MCF10A cells treated as in (d). Scale bars throughout the panel are 50 µm.
Supplementary Fig. 19: Autophagy controls cell proliferation downstream of LATS1/2 kinases.
(a) Representative BrdU images of MCF10A cells exposed to LATS1/2 siRNAs, plated at low and high densities. The cells were initially exposed to control, ATG7/ATG10 or ATG16L1 siRNAs. Scale bars are 10 µm.

(b) Quantification of BrdU-positive MCF10A cells treated as in (a). Bars represent the mean±s.d. (n=3; ***P<0.001, **P<0.01, *P<0.05, NS – not significant; two-tailed t-test).

(c) Schematic representation of the roles of the YAP/TAZ-actomyosin-autophagy axis in the clearance of aggregate-prone proteins (such as polyQ-htt), survival to metabolic stress and cell proliferation.
Fig. 1a  MCF10A - DMSO
GAPDH  
LC3  
(Higher exp.)
GAPDH  
LC3  

Fig. 11
GAPDH  
LC3  
(Higher exp.)
GAPDH  
LC3  
(Lighter exp.)

Fig. 2h  MCF10A - BafA1
GAPDH  
LC3  
(Higher exp.)
GAPDH  
LC3  

Fig. 2h
LATS1  MLC2  GAPDH  
MYH9  LC3  
MYH10  LC3  
(Higher exp.)

Fig. 3f
GAPDH  
LC3  

Fig. 4a  
GFP  
LC3  
(Higher exp.)
LC3  
(Lighter exp.)
GAPDH  

Fig. 4a (DMSO)  
LC3 - DMSO  
(Higher exp.)
LC3 - DMSO

Fig. 4b  
MLC2  
GAPDH  

Fig. 4d (BafA1)  
MLC2-GFP  
LC3 - BafA1  
(Higher exp.)
LC3 - BafA1  
GAPDH (DMSO)  
GAPDH (BafA1)
Supplementary Fig. 20. Full scans of uncropped blots.
Supplementary Table 1. Fold regulation of autophagy genes using RT² Profiler™ PCR Array Human Autophagy (330231 QIAGEN) in YAP/TAZ–depleted compared to control HeLa cells.

| Position | Symbol  | Fold Regulation |
|----------|---------|----------------|
| G04      | TGM2    | -3.8107        |
| C11      | DRAM1   | -2.6111        |
| F02      | NFkB1   | -1.9656        |
| B09      | BCL2L1  | -1.7385        |
| F03      | NPC1    | -1.7326        |
| D08      | GABARAPL1 | -1.7246    |
| E12      | MAPK8   | -1.5434        |
| E02      | HSPA8   | -1.428         |
| A06      | ATG16L1 | -1.422         |
| C06      | CTSB    | -1.4011        |
| B08      | BCL2    | -1.3424        |
| A10      | ATG4B   | -1.3134        |
| B02      | ATG7    | -1.3033        |
| H01      | ACTB    | -1.2913        |
| E11      | MAPK14  | -1.2802        |
| B12      | BNP3    | -1.2699        |
| F11      | RGS19   | -1.2546        |
| F06      | PIK3R4  | -1.2527        |
| A07      | ATG16L2 | -1.2455        |
| B05      | BAD     | -1.2451        |
| B01      | ATG5    | -1.2397        |
| D02      | EIF4G1  | -1.2363        |
| G02      | SQSTM1  | -1.2289        |
| F12      | RPS6KB1 | -1.2272        |
| A08      | ATG3    | -1.2192        |
| A11      | ATG4C   | -1.1948        |
| D04      | FADD    | -1.1914        |
| D12      | HGS     | -1.1887        |
| E01      | HSP90AA1| -1.187         |
| B11      | BID     | -1.1822        |
| A02      | AMBRA1  | -1.177         |
| F08      | PTEN    | -1.175         |
| E10      | MAP1LC3B| -1.1633       |
| F07      | PRKAA1  | -1.1457        |
| A05      | ATG12   | -1.144         |
| A03      | APP     | -1.1289        |
| B06      | BAK1    | -1.1257        |
| G11      | UVRAG   | -1.1139        |
| A12      | ATG4D   | -1.11          |
| C04      | CDKN2A  | -1.11          |
| A01      | AKT1    | -1.1085        |
| B10      | BECN1   | -1.1041        |
| C12      | DRAM2   | -1.0973        |
| F01      | MTOC    | -1.0768        |
| E08      | LAMP1   | -1.0707        |
| C02      | CASP8   | -1.068         |
| A09      | ATG4A   | -1.0609        |

| F04 | PIK3C3 | -1.0568 |
| D09 | GABARAPL2 | -1.0528 |
| D10 | HADC1 | -1.0491 |
| G12 | WIP1 | -1.0007 |
| D11 | HADC6 | 1.0277 |
| E03 | HTT | 1.0376 |
| C05 | CLN3 | 1.0493 |
| D06 | GAA | 1.0867 |
| C03 | CDKN1B | 1.0942 |
| E09 | MAP1LC3A | 1.0964 |
| D05 | FAS | 1.102 |
| B04 | ATG9B | 1.1075 |
| C10 | DAPK1 | 1.1075 |
| D03 | ESR1 | 1.1075 |
| E04 | IFNG | 1.1075 |
| E05 | IGF1 | 1.1075 |
| E06 | INS | 1.1075 |
| E07 | IRGM | 1.1075 |
| F05 | PIK3CG | 1.1075 |
| G05 | TMEM74 | 1.1075 |
| G06 | TNF | 1.1075 |
| G07 | TNFSF10 | 1.1075 |
| G10 | ULK2 | 1.1075 |
| B07 | BAX | 1.1141 |
| C07 | CTSD | 1.1226 |
| G08 | TP53 | 1.1285 |
| B03 | ATG9A | 1.135 |
| F10 | RB1 | 1.1687 |
| D01 | EIF2AK3 | 1.1715 |
| G03 | TGFBI | 1.2674 |
| F09 | RAB24 | 1.2683 |
| D07 | GABARAP | 1.3437 |
| C09 | CXCR4 | 1.3884 |
| A04 | ATG10 | 1.4063 |
| C08 | CTSS | 1.642 |
| G01 | SNCA | 1.9624 |
| G09 | ULK1 | 2.0837 |
| H02 | B2M | 1.3602 |
| H03 | GAPDH | -1.1553 |
| H04 | Hprt1 | -1.15 |
| H05 | RPLP0 | -1.0238 |
| H06 | HGDC | 1.1075 |
| H07 | RTC | 1.2191 |
| H08 | RTC | 1.1557 |
| H09 | RTC | 1.1706 |
| H10 | PPC | 1.256 |
| H11 | PPC | 1.1915 |
| H12 | PPC | 1.2861 |
Supplementary Table 2: Dharmacon siRNA sequences.

| Target          | Dharmacon identifier (smart pool) | Sequences                                                                 |
|-----------------|-----------------------------------|---------------------------------------------------------------------------|
| human ATG7      | L-020112-00                       | J-020112-05: CCAACACACUCGAGUCUUU                                          |
|                 |                                   | J-020112-06: GAUCUAAUCUCAACUGA                                            |
|                 |                                   | J-020112-07: GCCCACAGAUGGAGUAGCA                                           |
|                 |                                   | J-020112-08: GCCAGAGGAUUCAACUGA                                            |
| human ATG10     | L-019426-01                       | J-019426-09: CGUCUCAGGAUGAACGAAA                                          |
|                 |                                   | J-019426-10: AGGAAUUGCGGCAGAAGA                                            |
|                 |                                   | J-019426-11: GGAGGAGGCUUUCGACUA                                            |
|                 |                                   | J-019426-12: CCAACGUUAUUGUCAGAA                                            |
| human ATG16L1   | L-021033-01                       | J-021033-09: UGUGGAGAUAUAUCGAAUA                                           |
|                 |                                   | J-021033-10: GGCAACACUCAGCCGACAA                                           |
|                 |                                   | J-021033-11: GCAUUGGAUAACGGAAC                                              |
|                 |                                   | J-021033-12: GUUAUUGUAUCCCGAAAC                                              |
| human LATS1     | L-004632-00                       | J-004632-05: GGUGAAGUCCGUCUAGCAA (LATS1_p1)                                |
|                 |                                   | J-004632-06: UAGCAUGGAUUUCGUAAC                                              |
|                 |                                   | J-004632-07: GGUAGUUCGCUUAUUCUAU (LATS_p2)                                 |
|                 |                                   | J-004632-08: GAAUGGUAUCUGGCAAC                                              |
| human LATS2     | L-003865-00                       | J-003865-09: GCACGCAUUUUACGAACUUC (LATS2_p1)                               |
|                 |                                   | J-003865-10: ACACUCACUCGCCCCAAU                                             |
|                 |                                   | J-003865-11: AAUCAGAUAUUCCUUUGUG (LATS_p2)                                 |
|                 |                                   | J-003865-12: GAAGUGAAACCGCACAAC                                              |
| human YAP1      | L-012200-00                       | J-012200-05: GCACCUAUCACUCUGAGAG (YAP_p1)                                 |
|                 |                                   | J-012200-06: UGAGAAACAUGACCA                                            |
|                 |                                   | J-012200-07: GGUCAGAUAUCCUUUAA (YAP_p2)                                  |
|                 |                                   | J-012200-08: CCACCAAGCUGAUAAC                                              |
| human WWTR1 (TAZ) | L-016083-00                  | J-016083-05: CCGCAGGGCUCAUGAGUAU                                           |
|                 |                                   | J-016083-06: GCACAAACACCCCAUGAACA (TAZ_p1)                                |
|                 |                                   | J-016083-07: AGGAAACAACGUUGACUA                                             |
|                 |                                   | J-016083-08: CCAACUCUCUGAAGAUCUC (TAZ_p2)                                |
| Control (Non-   | D-001810-10                       | Seq_1: UGGUUUACAUUGUCGACUAA                                             |
| targeting pool) |                                   | Seq_2: UGGUUUAAUGUGUGA                                                 |
|                 |                                   | Seq_3: UGGUUUACAUUGUUCUAGA                                              |
|                 |                                   | Seq_4: UGGUUUACAUUGUUUCUAGA                                             |
| Gene   | Primers                                                                 |
|--------|------------------------------------------------------------------------|
| human ACTB | Fw: 5'-GAGCACAGAGCCTCGCCTTT-3'  
            | Rv: 5'-TCATCATCCATGTTGAGCTG-3' |
| human MLC2  | Fw: 5'-TTTGGGGAGAAGCTGAACGG-3'  
              | Rv: 5'-TCATGGATGAAACCTGAGGC-3' |
| human MYH9  | Fw: 5'-GGAAGGCTAAGCAAGGCTGA-3'  
              | Rv: 5'-ACTTATAGGCAAGGCTCAAGCC-3' |
| human MYH10 | Fw: 5'-GACCTGGAAAGCCCGGACC-3'  
              | Rv: 5'-GAAAGGCACCCACACAGAGCC-3' |
| human MYH14 | Fw: 5'-ACCTTGGACCTCGTGCCTTT-3'  
             | Rv: 5'-TCATCCGTTCCATGACCT-3'   |
| human ACTN1 | Fw: 5'-CAGACCCGAGGGAATCTAGAA-3'  
              | Rv: 5'-CAGGGTTCATATCCAGCAGCATC-3' |
| human DIAPH1 | Fw: 5'-CGACGGCGGCAAATCTAAGAA-3'  
            | Rv: 5'-CAGGTTCATATCCAGCAGCATC-3' |
| human RHOA  | Fw: 5'-CGTTAGTCCAGGCTCTGGTC-3'  
              | Rv: 5'-GCCATTGCTCAGGCAACGAA-3' |
| human RPLP0 | Fw: 5'-CTGCTCTGGAAGTGACAT-3'  
              | Rv: 5'-TAGTTGGACTTCCAGGCGA-3'  |
| human HPRT1  | Fw: 5'-ACAGTCAGCCGCACTTTCTTT-3'  
              | Rv: 5'-CAATACGACCAAATCCGTTG-3' |
| human GAPDH | Fw: 5'-ACAGTCAGCCGCACTTTCTTT-3'  
              | Rv: 5'-CAATACGACCAAATCCGTTG-3' |
| human CYR61 | Fw: 5'-AGAGGCTGAGGATCTGAC-3'  
              | Rv: 5'-CATTCCAAAACACAGGAACCC-3' |
| human CTGF  | Fw: 5'-GAGACCCGAGGGTTAATCGAC-3'  
              | Rv: 5'-GAGATGCACATTGTGCTCC-3'  |
| human YAP1   | Fw: 5'-CCTGCTTTGCGCATGAAACC-3'  
             | Rv: 5'-GTGCTGCTTGATGGATGG-3'   |
| mouse Ankrd1 | Fw: 5'-GAGACACCCCACTCGCATGAT-3'  
             | Rv: 5'-TTCCGACGACAGTTCTTGACC-3' |
| mouse Cyr61  | Fw: 5'-AGAGCTCTCGTCTTGGCC-3'  
              | Rv: 5'-CCAAGACGTTGAACGCGA-3'   |
| mouse Ctgf   | Fw: 5'-AGAAGTGTGACAGGGACTG-3'  
              | Rv: 5'-GTGCAACATTTTGGCAAGTG-3' |
| mouse Myl9    | Fw: 5'-CTCTGCAGAGGAAACC-3'  
              | Rv: 5'-CATGGCGAAGACATGGGAC-3'  |
| mouse Myh9    | Fw: 5'-AGAAAGCAGGGGAGTT-3'  
              | Rv: 5'-ATTCTTCACCGTCTTGGCGT-3' |
| mouse Myh10   | Fw: 5'-TTCCTGGGAACCTGAAGCG-3'  
              | Rv: 5'-CGGATAAATGGCACAAGGCA-3' |
| mouse Actb    | Fw: 5'-TAGTTGGACTTCCAGGTCG-3'  
              | Rv: 5'-TCATCCGTTGGAACGCTG-3'   |
| mouse Rplp0   | Fw: 5'-TAGTTGGACTTCCAGGTCG-3'  
              | Rv: 5'-TAGTTGGACTTCCAGGTCG-3'   |